Navigation Links
Can the relationship between doctors and drug companies ever be a healthy one?
Date:7/20/2009

Should the financial ties between doctors and drug companies be completely cut, or are healthy alliances between the two possible with the common aim of improving human health? A debate in this week's PLoS Medicine discusses whether the influence of drug company money on doctors is always a corrupting one.

The relationship between doctors and drug companies has been the subject of intense scrutiny in recent years, with some commentators arguing that the public health mission of doctors is incompatible with the pharmaceutical industry motive to maximize profits for shareholders. Emma D'Arcy the co-founder of www.myphid.com, an international networking site that allows healthcare workers and the pharmaceutical industry to communicate in a transparent way disagrees that relationship is fundamentally incompatible. She suggests that "authentic alliances" between doctors and the drug industry can be formed with the common aim of improving human health and safe and effective medicines. Pointing out that the drug industry remains an important source of funding for scientific meetings and continuing medical education, she outlines three ways in which healthy collaboration can be encouraged without needing to further regulate the industry. These include: teaching medical professionals to distinguish between clinical information and promotional material; ensuring transparency from both parties through networking sites such as www.myphid.com; and encouraging industry and doctors to follow an "everyday credo" to make sure interactions ultimately benefit the care of people living with disease and further medical scientific understanding.

Ray Moynihan of the University of Newcastle, New South Wales, Australia, argues that transparency is not enough to ensure that physicians' prescribing behaviour is not distorted by pharmaceutical influence. He cites evidence collected on the site of the non-profit group Healthy Skepticism (www.healthyskepticism.org), including a systematic review demonstrating that studies sponsored by pharmaceutical companies were more likely to have outcomes favouring their sponsor, and calls for the medical profession to disentangle itself completely from the money it accepts from the pharmaceutical industry. He highlights the case of pharmaceutical industry distortion of continuing medical education, in particular the ability of doctors to gain professional credits and company sponsored events. Giving examples of education for doctors in Australia where sponsors have even determined topics and speakers for seminars, he concludes that there should be a complete ban on all industry funding of continuing medical education, whether direct or indirect. Complete disentanglement is a healthier alternative, argues Moynihan, and strategies such as the American Medical Student Associations "PharmFree" campaign, which has advocated the severing of financial ties, prefigure "a future where fewer doctors will be prescribing under the influence of industry."


'/>"/>

Contact: Andrew Hyde
press@plos.org
44-122-346-3330
Public Library of Science
Source:Eurekalert

Related medicine news :

1. Snoring Isn't Sexy, LLC Announces Professional Relationship with the American Sleep Apnea Association
2. Availity Announces Strategic Relationship With Anthem Blue Cross and Blue Shield in Kentucky
3. MicroMass Hires Veteran Relationship Marketing Strategist Richard Patterson As VP, Group Account Director
4. First Book Focusing on How "The Secret Pain Women Won't Talk About" Affects Relationships
5. Harden Healthcare Expands Relationship with Sandata Technologies
6. Data Development Worldwide Helps Pharmaceutical Marketers Optimize Relationship Marketing to Patients
7. She Just Wanted to Dance Again: Navigate the Exchange of Parent-Caregiving Relationships Through Example, Advice
8. What is the relationship between hepatocellular carcinoma and type 2 diabetes mellitus?
9. Innovative New Wellness and Nutrition Program Leverages Latest Understanding of Relationship Between Diet and Genes
10. Couples in Good Relationships Sleep Better
11. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Sun Health registered ... the organization’s successful Care Transitions program at the 9th Annual Orthopedic ... “Minimizing Costs in the Post-Acute Environment Through Effective Transitions of Care.” , Major ...
(Date:5/5/2016)... Diego, CA (PRWEB) , ... May 05, 2016 , ... ... travel nursing firm, is encouraging people all over the United States to thank a ... May 12, Aya Healthcare will donate $5 to the American Red Cross of San ...
(Date:5/5/2016)... Ohio (PRWEB) , ... May 05, 2016 , ... United ... Cycle. , Clark brings more than 15 years of experience within the healthcare ... from a successful career as the Director of Patient Financial Services at Spectrum Health. ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... for iOS and Android devices. VisualDx is the first point of care ... support across general medicine. The system speeds diagnosis, therapy decisions and patient ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... With May flowers, summer is just around ... it means a welcome respite from school and the ability to play all day and ... for their children or watch the little tykes themselves. Summer also means trips to the ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , May 5, 2016 /PRNewswire/ ... announced the addition of the  "Europe ... - 2016"  report to their offering.  ... ) , ,The latest research ... Highlights - 2016, provides comprehensive insights ...
(Date:5/4/2016)... , May 4, 2016  It,s time for an upgrade. There are many ... a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and ... well as a world class manufacturer of innovative technology.  Photo - ... ... ...
(Date:5/4/2016)... , May 4, 2016 ... completion of an alternative public offering (APO). This was ... operating company, Valeritas, Inc. and a private placement of ... at $5.00 per share. Under the terms ... 3, 2016, Valeritas Holdings, Inc. will trade on the ...
Breaking Medicine Technology: